MX373378B - Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos. - Google Patents

Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos.

Info

Publication number
MX373378B
MX373378B MX2012010707A MX2012010707A MX373378B MX 373378 B MX373378 B MX 373378B MX 2012010707 A MX2012010707 A MX 2012010707A MX 2012010707 A MX2012010707 A MX 2012010707A MX 373378 B MX373378 B MX 373378B
Authority
MX
Mexico
Prior art keywords
glycosphingolipids
sialoglycosphingolipids
mixture
water
compound selected
Prior art date
Application number
MX2012010707A
Other languages
English (en)
Other versions
MX2012010707A (es
Inventor
Beltramo Dante
Bianco Ismael
Alasino Valeria
Leonhard Victoria
Original Assignee
Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet Star
Centro De Excelencia En Productos Y Procesos De Cordoba Ceprocor Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet Star, Centro De Excelencia En Productos Y Procesos De Cordoba Ceprocor Star filed Critical Consejo Nacional De Investigaciones Cientificas Y Tecn Conicet Star
Publication of MX2012010707A publication Critical patent/MX2012010707A/es
Publication of MX373378B publication Critical patent/MX373378B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0291—Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se revelan composiciones farmacéuticas solubles en agua, que comprenden al menos una sustancia terapéuticamente activa y al menos un compuesto seleccionado entre los sialoglicoesfingolípidos, los glicoesfingolípidos o una mezcla de sialoglicoesfingolípidos y glicoesfingolípidos, en donde al menos una de las sustancias terapéuticamente activas es una droga de características hidrofóbicas. En particular, se revelan composiciones, inyectables y estériles, formadas por nano-micelas de glicoesfingolípidos o glicoesfingolípidos modificados, las cuales pueden estar cubiertas en forma no covalente con albúmina y que permiten el transporte y la liberación controlada de moléculas altamente hidrofóbicas.
MX2012010707A 2010-03-17 2011-03-14 Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos. MX373378B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ARP100100854A AR093275A1 (es) 2010-03-17 2010-03-17 Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
PCT/ES2011/070174 WO2011113981A1 (es) 2010-03-17 2011-03-14 Una composición farmacéutica soluble en agua que comprende al menos una sustancia terapéuticamente activa de características hidrofóbicas y al menos un compuesto seleccionado entre los sialoglicoesfingolípidos, los glicoesfingolípidos o una mezcla de sialoglicoesfingolípidos y glicoesfingolípidos

Publications (2)

Publication Number Publication Date
MX2012010707A MX2012010707A (es) 2013-04-03
MX373378B true MX373378B (es) 2020-07-06

Family

ID=44648461

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010707A MX373378B (es) 2010-03-17 2011-03-14 Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos.

Country Status (12)

Country Link
US (1) US8956645B2 (es)
EP (1) EP2561861B1 (es)
CN (1) CN102905693A (es)
AR (1) AR093275A1 (es)
AU (1) AU2011229019B2 (es)
BR (1) BR112012023396A2 (es)
CA (1) CA2797295C (es)
ES (1) ES2879860T3 (es)
MX (1) MX373378B (es)
NZ (1) NZ602990A (es)
PE (1) PE20130064A1 (es)
WO (1) WO2011113981A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106974889A (zh) * 2017-03-14 2017-07-25 重庆大学 载药神经节苷脂胶束及其制备方法和应用
US20220054651A1 (en) * 2018-12-14 2022-02-24 Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet) Ternary micellar complex composed of a sialoglycosphingolipid, a therapeutically active substance and an antibody
CN113827738B (zh) * 2020-06-08 2024-04-09 沈阳药科大学 唾液酸修饰地塞米松棕榈酸酯脂质体及其制备和应用
WO2025149893A1 (en) * 2024-01-09 2025-07-17 Química Luar S.R.L. A pharmaceutical composition

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5637569A (en) * 1991-11-11 1997-06-10 Symbicom Aktiebolag Ganglioside analogs
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
JP3499604B2 (ja) 1994-07-25 2004-02-23 財団法人神奈川科学技術アカデミー スフィンゴ糖脂質ミセルからなる薬物担体
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
HUP9701554D0 (en) 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
EP1100494A1 (en) 1998-07-30 2001-05-23 Novopharm Biotech, Inc. Pharmaceutically composition comprising an aqueous solution of paclitaxel and albumin
WO2005011632A1 (ja) 2003-08-01 2005-02-10 National Institute Of Advanced Industrial Science And Technology 糖鎖を有する標的指向性および腸管吸収制御性リポソームならびにそれを含む癌治療薬および診断薬
WO2005046637A2 (en) * 2003-11-14 2005-05-26 Het Nederlands Kanker Instituut Pharmaceutical formulations employing short-chain sphingolipids and their use
JP2008523151A (ja) 2004-12-14 2008-07-03 トランセイブ， インク． 生理活性物質を含む脂質粒子、その調製法及び使用法
JPWO2007018275A1 (ja) * 2005-08-11 2009-02-19 独立行政法人産業技術総合研究所 ローリングモデルに基づく、送達媒体の設計
US20090169610A1 (en) * 2006-02-03 2009-07-02 Noboru Yamazaki Liposome Preparation
ES2776100T3 (es) * 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
CN1846692A (zh) * 2006-05-15 2006-10-18 沈阳药科大学 多烯紫杉醇长循环脂质体剂型及其制备方法
US8425900B2 (en) * 2007-04-30 2013-04-23 Agency For Science, Technology And Research Method of delivering a protein into a cell
CN101439032A (zh) 2007-11-22 2009-05-27 沈阳沃森药物研究所 一种紫杉醇脂质复合物及其注射用胶束组合物
CN101439033A (zh) 2007-11-22 2009-05-27 沈阳沃森药物研究所 一种多烯紫杉醇脂质复合物及其注射用胶束组合物
CN101439020A (zh) 2007-11-22 2009-05-27 沈阳沃森药物研究所 一种多烯紫杉醇纳米脂质载体及其制备方法

Also Published As

Publication number Publication date
ES2879860T3 (es) 2021-11-23
CA2797295A1 (en) 2011-09-22
US8956645B2 (en) 2015-02-17
AU2011229019A1 (en) 2012-11-08
CN102905693A (zh) 2013-01-30
PE20130064A1 (es) 2013-02-01
AR093275A1 (es) 2015-05-27
CA2797295C (en) 2014-11-18
AU2011229019B2 (en) 2016-11-17
MX2012010707A (es) 2013-04-03
EP2561861B1 (en) 2021-02-24
BR112012023396A2 (pt) 2022-08-02
NZ602990A (en) 2014-07-25
US20130195924A1 (en) 2013-08-01
EP2561861A1 (en) 2013-02-27
EP2561861A4 (en) 2014-10-22
WO2011113981A1 (es) 2011-09-22

Similar Documents

Publication Publication Date Title
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
BR112012021086A2 (pt) composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112014010291A2 (pt) composições de lipossoma combinacionais para terapia de câncer
FI20116138A7 (fi) Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
EA201492292A1 (ru) Препарат антител
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
CL2012000319A1 (es) Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística.
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
MX2011011829A (es) Composicion para suministro sostenido de farmaco que comprende un aglutinante geopolimerico.
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
MX373378B (es) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos.
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
EA201490573A1 (ru) Соединение бензотиазолона
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento

Legal Events

Date Code Title Description
FG Grant or registration